close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Halberd Corporation

< Previous 1 2 Next >
Halberd's PTSD/Alzheimer's R&D Reveals Link to Potential Obesity Cure
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd and GTX Corp. Sign Scientific Collaboration and Reseller Agreement
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers GTXO HALB
Halberd Corporation CEO Letter
From Halberd Corporation
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Tickers HALB
Halberd's VITASHIELDMAX(TM) Immunity Support Product Available on Amazon
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd and heliosDX of RushNet Enter Scientific Collaboration Agreement
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB RSHN
Halberd's Treatment Eradicates Primary Building Block of Alzheimer’s Disease
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Corporation Appoints Anthony Mirabelli Vice-President, Mergers & Acquisitions
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Corporation Alzheimer's Disease Treatment Tests Yield Outstanding Results
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Receives Patent for Treatment of Cockayne Syndrome - May Provide Pathway to Slow Aging
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Files Provisional Patent Application - Furthering Efforts on Alzheimer's Disease
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
Tickers HALB
Halberd Corp. VITA-SHIELD-MAX(TM) Available - Buy Now!
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd’s Disease Elimination Technology R&D at Youngstown State University (YSU) Draws Attention of CBS Affiliate WKBN
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Corporation Adds Blood-Borne Disease Treatment Capability With Addition Of Noted Nephrologist
From Halberd Corporation
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Corporation's VITA-SHIELD-MAX(TM) Immunity Support Product Shipped
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Corporation Successfully Establishes Disease Eradication Proof-of-Concept - "Never Before Accomplished"
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
Tickers HALB
Halberd Corp. Advances the Elimination of Antigens Present in Alzheimer’s Disease & PTSD/Chronic Traumatic Encephalopathy
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
Tickers HALB
Halberd Corporation CEO Letter
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
Tickers HALB
Halberd Corp. Discovers a Proprietary Disease-Causing Antigen Removal Process
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Corporation's Proprietary Technology for Alzheimer’s Disease Enters Stage 4 of 7 Stage Process
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Corporation Successfully Conjugates Metallic Particles and Antibodies Against Alzheimer's Disease-Associated Antigens
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Corporation Undertakes Process Toward the Elimination of Alzheimer’s Disease
From Halberd Corporation
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Corporation Creates Two New and Stronger SARS-CoV-2 Neutralizing Antibodies
From Halberd Corporation
Via AccessWire
Topics Animal Testing Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Corp. Files Provisional Patent Application Complementing Patented Extracorporeal Radio Frequency/Laser Projects
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Corporation Successfully Conjugates Metallic Particles and E. Coli Antibody
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
"MarketWatch" Features Halberd Corporation With Prominent Pharmaceutical Companies on New Treatments for COVID-19
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Corporation Reports Successful Conjugation of Metallic Particles & SARS-CoV-2 Proprietary Monoclonal Antibody
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Corporation Begins Testing of Patented Process for Laser Eradication of Disease
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Corp. Designated as a BREAKOUT Stock to Watch in Investor Publications
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Corporation Appoints New Chief Technical Officer to Optimize Upcoming Experiments On Radio Frequency and Laser Eradication of Disease
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Treating and Curing Covid-19 Infection Utilizing a Laser
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers HALB
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today